Business
Mesoblast shares savaged on poor COVID trial results – Sydney Morning Herald
The stem cell treatment hopeful plunged 41 per cent at the open after revealing its COVID research was unlikely to meet its goals.
The company, will complete the study, which had been aiming to recruit 300 patients, using the 223 patients already enrolled.
Its the second piece of tough news for Mesoblast, which is backed by high profile investors including billionaire Alex Waislitz, to be released this week, after phase 3 trial results of its heart failure drug caused the stock to plunge at the start of the week. The company released data on Tuesday showing its other product, Revascor, showed reduction in mortality of up to…
-
General21 hours agoAbattoir worker in serious condition after workplace accident in Echuca
-
General22 hours agoWoman who reported NSW MP Gareth Ward’s alleged sex crimes cross-examined
-
Noosa News12 hours agoFull house as Minister shares vision for Sunshine Coast transport
-
General14 hours agoIran-Israel war live updates: Missiles fired at US bases in Qatar as war expands